Amer J Perinatol
DOI: 10.1055/s-0037-1612640
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Development of a Clinical Risk Assessment Tool for 6-Week Postpartum Visit Nonadherence

Fred Qafiti1, Sangeeta Kaur2, Ray Bahado-Singh2
  • 1Oakland University William Beaumont School of Medicine, Rochester, Michigan
  • 2Department of Obstetrics and Gynecology, Oakland University William Beaumont School of Medicine, Beaumont Hospital, Royal Oak, Michigan
Further Information

Publication History

17 July 2017

10 November 2017

Publication Date:
13 December 2017 (eFirst)

Abstract

Objective The 6-week postpartum visit (6WPP) is integral in addressing postpartum medical concerns. Failure to attend this routine visit is a measure of suboptimal care. This study aims to identify patients at risk of 6WPP nonadherence by developing a novel point-based risk scoring system.

Methods In this retrospective case–control study (n = 587), a randomly selected subgroup, that is, the “test” group (n = 303), was used to develop the model. The remaining patients were used as an independent “validation” group (n = 284) to assess the model performance.

Results Five factors were found to correlate with 6WPP nonadherence. Positive correlations include: Medicaid health insurance (odds ratio [OR]: 2.40, 95% confidence interval [CI]: 1.38–4.15); prenatal care initiated at ≥ 14 weeks' gestation (OR: 1.82, 95% CI: 1.11–2.96); and maternal age < 24.0 years (OR: 2.02, 95% CI: 1.13–3.61). Factors negatively correlated with nonadherence include: “married” marital status (OR: 0.50, 95% CI: 0.30–0.84) and primiparity (OR: 0.51, 95% CI: 0.30–0.85). The final scoring system demonstrates significant predictive power in both the test and validation groups (respectively, area under the curve = 0.682, p < 0.001 and 0.629, p < 0.001).

Conclusion This risk assessment tool relies on routinely collected data, making its implementation simple. Applying it in the clinical setting allows for early, targeted intervention aimed at minimizing 6WPP nonadherence.